Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Arbutus Biopharma (NASDAQ:ABUS) with a $4 price target.
June 05, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on Arbutus Biopharma with a $4 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a specific price target of $4 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100